Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El salvador, central america

Clinical Microbiology and Infection

Volumn 19, Issue 12, 2013, Pages

  Holguín, Á ^a   Yebra, G ^a   Martin L ^a   de Pineda, A T ^b   Ruiz, L E ^c   Quezada, A Y ^c   Nieto, A I ^c   Escobar, G ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Diabetes Association of El Salvador   (El Salvador)

^c Ministry of Health of El Salvador   (El Salvador)

^d Hospital Nacional de Ninos Benjamin Bloom   (El Salvador)

Author keywords

Central America; Dried blood spots; El Salvador; Human immunodeficiency virus type 1; Transmitted drug resistance

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; EL SALVADOR; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS LOAD; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CENTRAL AMERICA; DRIED BLOOD SPOTS; EL SALVADOR; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; TRANSMITTED DRUG RESISTANCE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; COHORT STUDIES; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; EL SALVADOR; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POVERTY; YOUNG ADULT;

EID: 84888074442     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12264     Document Type: Article

References (28)

1. UNAIDS. 2011. 2010 Report on the global AIDS epidemic. Available at: http://www.unaids.org/documents/20101123_GlobalReport_em.pdf (last accessed 3 June 2013).
2. WHO UNAIDS UNICEF. 2011. Global HIV/AIDS Response. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf (last accessed 3 June 2013).
3. Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-371.
4. Hamers RL, Wallis CL, Kityo C et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750-759.
5. Gupta RK, Jordan MR, Sultan BJ et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250-1258.
6. WHO. 2012. World Health Organization HIV drug resistance report. Available at: http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html (last accessed 3 June 2013).
7. Castillo J, Arteaga G, Mendoza Y et al. HIV transmitted drug resistance in adult and pediatric populations in Panama. Rev Panam Salud Publica 2011; 30: 649-656.
8. Ávila-Ríos S, García-Morales C, Garrido-Rodríguez D et al. National prevalence and trends of HIV transmitted drug resistance in Mexico. PLoS ONE 2012; 6: e27812.
9. Lloyd B, O'Connell RJ, Michael NL et al. Prevalence of resistance mutations in HIV-1-infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses 2008; 24: 529-535.
10. Murillo W, Paz-Bailey G, Morales S et al. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol 2010; 49: 239-244.
11. Holguín A, Erazo K, Escobar G et al. Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in Honduras and El Salvador during 1989-2009. Pediatr Infect Dis J 2011; 30: e82-e87.
12. Murillo W, Lorenzana de Rivera I, Albert J, Guardado ME, Nieto AI, Paz-Bailey G. Prevalence of transmitted HIV-1 drug resistance among female sex workers and men who have sex with men in El Salvador, Central America. J Med Virol 2012; 84: 1514-1521.
13. WHO. 2010. WHO manual for HIV drug resistance testing using dried blood spot specimens. Available at: http://www.who.int/hiv/topics/drugresistance/dbs_protocol.pdf (last accessed 3 June 2013).
14. de Mulder M, Holguín Á. Dried blood spots for monitoring HIV infection in Public Health Programs in developing countries. Enferm Infecc Microbiol Clin 2013; 31: 100-107.
15. Gifford RJ, Liu TF, Rhee SY et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009; 25: 1197-1198.
16. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.
17. Johnson VA, Calvez V, Gunthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-164.
18. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-2739.
19. Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P. RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics 2010; 26: 2462-2463.
20. Sierra M, Thomson MM, Posada D et al. Identification of 3 phylogenetically related HIV-1 BG intersubtype circulating recombinant forms in Cuba. J Acquir Immune Defic Syndr 2007; 45: 151-160.
21. Ahumada-Ruiz S, Flores-Figueroa D, Toala-Gonzalez I, Thomson MM. Analysis of HIV-1 pol sequences from Panama: identification of phylogenetic clusters within subtype B and detection of antiretroviral drug resistance mutations. Infect Genet Evol 2009; 9: 933-940.
22. Escoto-Delgadillo M, Vázquez-Valls E, Ramírez-Rodríguez M et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005; 6: 403-409.
23. Parham L, de Rivera IL, Murillo W et al. Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004. AIDS Res Hum Retroviruses 2011; 27: 1055-1059.
24. Ávila-Ríos S, Mejía-Villatoro CR, Garcia-Morales C et al. Prevalence and patterns of HIV transmitted drug resistance in Guatemala. Rev Panam Salud Publica 2011; 30: 641-648.
25. Health Ministry of El Salvador. 2010. National STD/HIV-AIDS Programme - Encuesta centroamericana de vigilancia de comportamiento sexual y prevalencia de VIH/ITS en poblaciones vulnerables. Available at: http://www.pasca.org/sites/default/files/ES_ESTUDIO3_ECVC_2010_0.pdf (last accessed 3 June 2013).
26. Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother 2004; 48: 4864-4868.
27. Bertagnolio S, Rodríguez-Díaz RA, Fuentes-Romero LL et al. Transmitted HIV drug resistance among drug-naive subjects recently infected with HIV in Mexico City: a World Health Organization survey to classify resistance and to field test two alternative patient enrollment methods. Clin Infect Dis 2012; 54(Suppl 4): S328-S333.
28. Viani RM, Hsia K, Hubbard P et al. Prevalence of primary HIV-1 drug resistance in pregnant women and in newly diagnosed adults at Tijuana General Hospital, Baja California. Mexico Int J STD AIDS 2007; 18: 235-238.